What is Redesign Science?
Redesign Science operates at the intersection of computational physics and cellular biology. The company's core technology, the NUVO platform, utilizes atomic-level molecular dynamics to simulate complex biomolecular systems. By integrating these physics-based simulations with generative AI, Redesign Science is able to identify and optimize first-in-class small molecule therapeutics with unprecedented precision. This methodology allows the firm to target the structural protein interactome, a notoriously difficult area of biology, to develop innovative treatments for complex diseases. Their market position is defined by a shift away from traditional trial-and-error drug discovery toward a predictive, data-driven model that enhances control over cellular biology.
How much funding has Redesign Science raised?
Redesign Science has raised a total of $15M across 1 funding round:
Angel/Seed
$15M
Angel/Seed (2021): $15M with participation from Refactor Capital, Preface Ventures, Third Kind Venture Capital, Collaborative Fund, Notation Capital, HawkTail, 5Y Capital, and Acequia Capital
Key Investors in Redesign Science
Refactor Capital
Refactor Capital is an early-stage venture capital firm that focuses on investing in hard tech founders who are addressing fundamental human problems.
Preface Ventures
Preface Ventures specializes in early-stage investments, focusing on founders who are developing innovative enterprise infrastructure and software solutions.
Third Kind Venture Capital
Third Kind Venture Capital is a venture capital firm specializing in early-stage investments with a focus on consumer internet, software, and financial services.
What's next for Redesign Science?
With the successful closure of this funding round, Redesign Science is poised to accelerate the development of its internal therapeutics pipeline. The strategic focus will likely shift toward validating its TPIM candidates in preclinical settings and expanding the computational capabilities of the NUVO platform. As the company matures, the integration of generative AI will remain a critical differentiator, enabling the firm to tackle increasingly complex biological challenges. Investors are closely monitoring the company's ability to translate its simulation-driven insights into clinical-stage assets, which will be the primary catalyst for future valuation growth and potential strategic partnerships within the pharmaceutical industry.
See full Redesign Science company page
